Impact of Timing of PD Assessments on Measures of Platelet Reactivity in Patients Undergoing PCI Treated With Cangrelor

Impact of Timing of Pharmacodynamic Assessments on Measures of Platelet Reactivity in Patients Undergoing Percutaneous Coronary Intervention Treated With Cangrelor

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04668495

Enrollment

Registered

2020-12-16

Start date

2021-01-28

Completion date

2021-07-20

Last updated

2021-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

This study is assessing the impact of timing of PD assessments on measures of platelet reactivity in patients undergoing PCI treated with cangrelor.

Detailed description

Cangrelor is characterized by reversible binding to the P2Y12 receptor and is promptly inactivated through dephosphorylation by ectonucleotidase leading to its very short plasma half-life. Consequently the timing at which PD assessments are performed after blood sample collection may impact measures of platelet reactivity in patients treated with cangrelor. We therefore hypothesize that measures of platelet inhibitory effects observed in cangrelor treated patients will reduce with time following blood sampling.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 100 Years

Inclusion criteria

* Age \> 18 years old * CAD patients (stable CAD, NSTE-ACS, or STEMI) undergoing PCI and treated with cangrelor per standard of care. * Treated with aspirin prior to the PCI procedure per standard of care

Exclusion criteria

* Treatment with an oral P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) within past 10 days * Treatment with oral anticoagulation (vitamin K antagonist, dabigatran, apixaban, rivaroxiban) within past 3 days * Treatment with a glycoprotein IIb/IIIa inhibitor during PCI * Fibrinolytics within 48 hours * Known hemoglobin\<10 gm/dL * Known platelet count \<80x106/mL * Active bleeding or hemodynamic instability * Known end stage renal disease on hemodialysis * Known severe hepatic dysfunction

Design outcomes

Primary

Measure	Time frame	Description
Change in platelet reactivity	wiithin 30 min, 1 hour, 2 hours, and 4 hours of blood sampling	measure of change platelet reactivity at time points

Countries

United States

Outcome results